Cover |
12 Months Ended |
|---|---|
|
Dec. 31, 2021
shares
| |
| Document Information [Line Items] | |
| Document Type | 20-F/A |
| Amendment Flag | true |
| Amendment Description | This Amendment on Form 20-F/A (the "Amendment") amends the Annual Report on Form 20-F of XORTX Therapeutics Inc. ("XORTX" or the "Company") for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on May 3, 2022 (the "Original Form 20-F"). This Amendment is being filed solely for the purpose of including disclosure that the Company inadvertently omitted from Item 5 of the Original Form 20-F relating to Use of Proceeds of the US IPO Financing (as defined in Item 5), a breakdown of R&D expenditures, a comparative analysis of the 12 months ended December 31, 2021, and disclosure of related party names. This Amendment does not reflect events occurring after the filing of the Original Form 20-F and does not modify or update the disclosure therein in any way other than as required to reflect the amendments described herein and reflected below. No other changes have been made to the Original Form 20-F. The filing of this Amendment should not be understood to mean that any statements contained herein are true or complete as of any date subsequent to the date of the original filing of the Original Annual Report. Accordingly, this Amendment should be read in conjunction with our filings made with the Securities and Exchange Commission subsequent to the filing of the Original Form 20-F. |
| Document Registration Statement | false |
| Document Annual Report | true |
| Document Transition Report | false |
| Document Shell Company Report | false |
| Document Period End Date | Dec. 31, 2021 |
| Document Fiscal Period Focus | FY |
| Document Fiscal Year Focus | 2021 |
| Current Fiscal Year End Date | --12-31 |
| Entity File Number | 001-40858 |
| Entity Registrant Name | XORTX Therapeutics Inc. |
| Entity Central Index Key | 0001729214 |
| Entity Incorporation, State or Country Code | A1 |
| Entity Address, Address Line One | 3710 33rd Street |
| Entity Address, Address Line Two | NW Calgary |
| Entity Address, City or Town | Alberta |
| Entity Address, Country | CA |
| Entity Address, Postal Zip Code | T2L 2M1 |
| Title of 12(b) Security | Common Shares |
| Trading Symbol | XRTX |
| Security Exchange Name | NASDAQ |
| Entity Well-known Seasoned Issuer | No |
| Entity Voluntary Filers | No |
| Entity Current Reporting Status | Yes |
| Entity Interactive Data Current | Yes |
| Entity Filer Category | Non-accelerated Filer |
| Entity Emerging Growth Company | true |
| Elected Not To Use the Extended Transition Period | true |
| Document Accounting Standard | International Financial Reporting Standards |
| Entity Shell Company | false |
| Entity Bankruptcy Proceedings, Reporting Current | false |
| Entity Common Stock, Shares Outstanding | 12,989,678 |
| Auditor Name | Smythe LLP |
| Auditor Location | Vancouver, Canada |
| Auditor Firm ID | 995 |
| Business Contact [Member] | |
| Document Information [Line Items] | |
| Entity Address, Address Line One | 3710 33rd Street |
| Entity Address, Address Line Two | NW Calgary |
| Entity Address, City or Town | Alberta |
| Entity Address, Country | CA |
| Entity Address, Postal Zip Code | T2L 2M1 |
| City Area Code | 403 |
| Local Phone Number | 455-7727 |
| Contact Personnel Name | Amar Keshri |
| Contact Personnel Email Address | akeshri@xortx.com |